共查询到20条相似文献,搜索用时 15 毫秒
1.
Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase. , the drug inhibits conversion of pregnenolone to progesterone but does not alter conversion of cholesterol to pregnenolone nor progesterone to corticoid hormones. When given orally to rats, trilostane inhibits corticosterone and aldosterone production and elevates circulating levels of pregnenolone at doses lower than those that produce adrenal hypertrophy or inhibit gonadal steroidogenesis. 相似文献
2.
Gooljarsingh LT Lakdawala A Coppo F Luo L Fields GB Tummino PJ Gontarek RR 《Protein science : a publication of the Protein Society》2008,17(1):66-71
Matrix metalloproteinase 13 (MMP13) is a key enzyme implicated in the degradation of the extracellular matrix in osteoarthritis. Clinical administration of broad spectrum MMP inhibitors such as marimastat has been implicated in severe musculo-skeletal side effects. Consequently, research has been focused on designing inhibitors that selectively inhibit MMP13, thereby circumventing musculo-skeletal toxicities. A series of pyrimidine dicarboxamides were recently shown to be highly selective inhibitors of MMP13 with a novel binding mode. We have applied a molecular ruler to this exosite by dual inhibition studies involving a potent dicarboxamide in the presence of two metal chelators of different sizes. A larger hydroxamate mimic overlaps and antagonizes binding of the dicarboxamide to the exosite whereas the much smaller acetohydroxamate synergizes with the dicarboxamide. These studies elucidate the steric requirement for compounds that fit exclusively into the active site, a mandate for generating highly selective MMP13 inhibitors. 相似文献
3.
The first example of dual inhibitors for matrix metalloproteinase (MMP) and cathepsin is described. An appropriate alignment of peptide-parts and two different specific functional groups in one molecule led to the discovery of a potent dual inhibitor (3a). 相似文献
4.
Bowers S Truong AP Neitz RJ Neitzel M Probst GD Hom RK Peterson B Galemmo RA Konradi AW Sham HL Tóth G Pan H Yao N Artis DR Brigham EF Quinn KP Sauer JM Powell K Ruslim L Ren Z Bard F Yednock TA Griswold-Prenner I 《Bioorganic & medicinal chemistry letters》2011,21(6):1838-1843
The SAR of a series of tri-substituted thiophene JNK3 inhibitors is described. By optimizing both the N-aryl acetamide region of the inhibitor and the 4-position of the thiophene we obtained single digit nanomolar compounds, such as 47, which demonstrated an in vivo effect on JNK activity when dosed orally in our kainic acid mouse model as measured by phospho-c-jun reduction. 相似文献
5.
McDermott LA Simcox M Higgins B Nevins T Kolinsky K Smith M Yang H Li JK Chen Y Ke J Mallalieu N Egan T Kolis S Railkar A Gerber L Luk KC 《Bioorganic & medicinal chemistry》2005,13(16):4835-4841
(+/-)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one (RO4383596) is a potent and selective inhibitor of the pro-angiogenic receptor tyrosine kinases KDR, FGFR, and PDGFR. This agent has an excellent pharmacokinetic profile and is highly efficacious in rodent models of angiogenesis upon oral administration. 相似文献
6.
Plantevin Krenitsky V Nadolny L Delgado M Ayala L Clareen SS Hilgraf R Albers R Hegde S D'Sidocky N Sapienza J Wright J McCarrick M Bahmanyar S Chamberlain P Delker SL Muir J Giegel D Xu L Celeridad M Lachowitzer J Bennett B Moghaddam M Khatsenko O Katz J Fan R Bai A Tang Y Shirley MA Benish B Bodine T Blease K Raymon H Cathers BE Satoh Y 《Bioorganic & medicinal chemistry letters》2012,22(3):1433-1438
In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors. Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930) as a development candidate, which is currently in Phase II clinical trial for IPF. 相似文献
7.
Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs
Chen JJ Dewdney N Lin X Martin RL Walker KA Huang J Chu F Eugui E Mirkovich A Kim Y Sarma K Arzeno H Van Wart HE 《Bioorganic & medicinal chemistry letters》2003,13(22):3951-3954
A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic data are discussed. 相似文献
8.
Isshiki Y Kohchi Y Iikura H Matsubara Y Asoh K Murata T Kohchi M Mizuguchi E Tsujii S Hattori K Miura T Yoshimura Y Aida S Miwa M Saitoh R Murao N Okabe H Belunis C Janson C Lukacs C Schück V Shimma N 《Bioorganic & medicinal chemistry letters》2011,21(6):1795-1801
The MAP kinase pathway is one of the most important pathways involved in cell proliferation and differentiation, and its components are promising targets for antitumor drugs. Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure. CH4987655 exhibits slow dissociation from the MEK enzyme, remarkable in vivo antitumor efficacy both in mono- and combination therapy, desirable metabolic stability, and insignificant MEK inhibition in mouse brain, implying few CNS-related side effects in human. An excellent PK profile and clear target inhibition in PBMC were demonstrated in a healthy volunteer clinical study. 相似文献
9.
Ohmoto K Okuma M Yamamoto T Kijima H Sekioka T Kitagawa K Yamamoto S Tanaka K Kawabata K Sakata A Imawaka H Nakai H Toda M 《Bioorganic & medicinal chemistry》2001,9(5):1307-1323
To identify new orally active inhibitors, further modification of 1 (ONO-6818) was performed. Peptidic derivatives 4b, 4c and 4n showed more potent inhibitory activity than nonpeptidic derivatives 3a-c. As a result, a series of peptidic inhibitors, 4a-s and 5a-v, were discovered. Among these N-aryl derivatives 5a-g, 5i, 5m and 5o-v showed oral activity. Their oral activity showed good correlation with their metabolic stability. Compounds 5h and 5j-l, which were extremely metabolically unstable in hamster plasma, did not show oral activity. Oral activity was considered to be determined by a combination of at least two factors: oral absorption and metabolic stability. 相似文献
10.
Watson NS Brown D Campbell M Chan C Chaudry L Convery MA Fenwick R Hamblin JN Haslam C Kelly HA King NP Kurtis CL Leach AR Manchee GR Mason AM Mitchell C Patel C Patel VK Senger S Shah GP Weston HE Whitworth C Young RJ 《Bioorganic & medicinal chemistry letters》2006,16(14):3784-3788
A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating an alanylamide P4 group, was designed and synthesised. Within this series, the N-2-(morpholin-4-yl)-2-oxoethyl derivative 24 was shown to be a potent, selective fXa inhibitor with good anticoagulant activity. Moreover, 24 possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species. 相似文献
11.
Kinoshita K Asoh K Furuichi N Ito T Kawada H Hara S Ohwada J Miyagi T Kobayashi T Takanashi K Tsukaguchi T Sakamoto H Tsukuda T Oikawa N 《Bioorganic & medicinal chemistry》2012,20(3):1271-1280
Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, especially non-small cell lung cancer (NSCLC). Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability. In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clinical candidate. 相似文献
12.
Iwanowicz EJ Kimball SD Lin J Lau W Han WC Wang TC Roberts DG Schumacher WA Ogletree ML Seiler SM 《Bioorganic & medicinal chemistry letters》2002,12(21):3183-3186
A series of retro-binding inhibitors of human alpha-thrombin was prepared to elucidate structure-activity relationships (SAR) and optimize in vivo performance. Compounds 9 and 11, orally active inhibitors of thrombin catalytic activity, were identified to be efficacious in a thrombin-induced lethality model in mice. 相似文献
13.
Cellular disintegrin and metalloproteinases (ADAMs) are a family of genes with a sequence similar to the snake venom metalloproteinases and disintegrins. ADAMTS-1 is a unique ADAM family protein with respect to the presence of thrombospondin type I motifs and the capacity to bind to the extracellular matrix. Because ADAMTS-1 has a potential zinc-binding motif in the metalloproteinase domain, we examined in this study whether ADAMTS-1 is an active metalloproteinase by means of the proteinase trapping mechanism of alpha2-macroglobulin. We found that the soluble type of ADAMTS-1 protein is able to form a covalent-binding complex with alpha2-macroglobulin. Furthermore, the point mutation within the zinc-binding motif of ADAMTS-1 protein eliminates its capacity to bind to alpha2-macroglobulin. These data demonstrate that the metalloproteinase domain of ADAMTS-1 is catalytically active. In addition, we showed that the removal of the pro-domain from the ADAMTS-1 precursor is impaired in the furin-deficient cell line, LoVo, and that the processing ability of the cells is restored by the co-expression of the furin cDNA. These data provide evidence that the ADAMTS-1 precursor is processed in vivo by furin endopeptidase in the secretory pathway. Consequently, ADAMTS-1 is an active metalloprotease that is associated with the extracellular matrix. This study strongly suggests that ADAMTS-1 may play a role in the inflammatory process through its protease activity. 相似文献
14.
Egbertson MS Moritz HM Melamed JY Han W Perlow DS Kuo MS Embrey M Vacca JP Zrada MM Cortes AR Wallace A Leonard Y Hazuda DJ Miller MD Felock PJ Stillmock KA Witmer MV Schleif W Gabryelski LJ Moyer G Ellis JD Jin L Xu W Braun MP Kassahun K Tsou NN Young SD 《Bioorganic & medicinal chemistry letters》2007,17(5):1392-1398
A 1,6-naphthyridine inhibitor of HIV-1 integrase has been discovered with excellent inhibitory activity in cells, good pharmacokinetics, and an excellent ability to inhibit virus with mutant enzyme. 相似文献
15.
H Morishima Y Koike M Nakano S Atsuumi S Tanaka H Funabashi J Hashimoto Y Sawasaki N Mino M Nakano 《Biochemical and biophysical research communications》1989,159(3):999-1005
BW-175 is a newly synthesized renin inhibitor which is a nonpeptidic, norleucine analog. Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D. Pepsin and angiotensin converting enzyme were hardly inhibited at 10(-4) M. BW-175 showed an oral bioavailability of 2.8% at 10 mg/kg and 9.7% at 30 mg/kg in rats. In normotensive, furosemide-treated high-renin marmosets, BW-175 (30 mg/kg p.o.) caused an intensive reduction in plasma renin activity and plasma angiotensin I formation, associated with a reduction in systolic blood pressure of 10-20 mm Hg for 2 hours. 相似文献
16.
A series of novel sulfonyl pyrrolidine derivatives were designed, synthesized and assayed for their inhibitory activities on matrix metalloproteinase 2 (MMP-2) and aminopeptidase N (AP-N). The results showed that these pyrrolidine derivatives exhibited highly selective inhibition against MMP-2 as compared with AP-N. Compounds 6a-d were more potent MMP-2 inhibitors than the positive control LY52. The structure-activity relationships were also briefly discussed. 相似文献
17.
Sonda S Kawahara T Murozono T Sato N Asano K Haga K 《Bioorganic & medicinal chemistry》2003,11(19):4225-4234
A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamide derivatives bearing an aralkylamino, alkylamino, benzoyl or phenylsulfonyl group at its side chain part at the 1-position on the piperidine ring was synthesized. They were evaluated for serotonin 4 (5-HT(4)) receptor agonist activity by testing their ability to contract the isolated guinea-pig ascending colon. 4-Amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)pentyl]piperidin-4-ylmethyl]benzamide (1a, Y-34959) and its related compounds possessed favorable pharmacological profiles for gastrointestinal motility. Unfortunately, the compound 1a showed low bioavailability when given orally presumably due to its poor intestinal absorption rate. Replacement of the 1-methylindol-3-yl carbonylamino moiety of 1a with an aralkylamino (or alkylamino) group did not improve the intestinal absorption rate. Replacement of the 1-methylindol-3-ylcarbonylamino moiety with a benzoyl or phenylsulfonyl group increased the intestinal absorption rate compared with 1a. These compounds revealed good pharmacological profiles for gastrointestinal motility and were superior to 1a in oral bioavailability. 相似文献
18.
19.
Metalloproteinases and their endogenous inhibitors are key components of an enzyme system which is important in a number of fundamental biochemical and cellular processes. Our recent work has focused on the role of a particular metalloproteinase, collagenase, and the role of an endogenous inhibitor of this enzyme in the control of neovascularization. The proteolytic degradation of extracellular matrix components by capillary endothelial cells (EC) has been shown to be one of the key prerequisites of the angiogenic process. As part of a study of the effect(s) of the inhibition of collagenase on neovascularization, we have recently reported the purification, characterization and partial NH2-terminal sequence of a cartilage-derived inhibitor (CDI) of angiogenesis in vivo and in vitro. Evidence is presented which suggests that one means of controlling deregulated vascular growth characteristic of a number of "angiogenic diseases" may be at the level of the control of metalloproteinase activity. 相似文献
20.
目的:探讨肺结核并发纤维化患者支气管肺泡灌洗液(BALF)及血清中基质金属蛋白9(MMP-9)及基质金属蛋白酶组织抑制剂l(TIMP-1)含量与肺纤维化及肺功能的关系.方法:酶联免疫(ELISA)法检测我院2009年3月至2009年9月68例肺结核并发纤维化患者(纤维化组)及30例无肺部疾病患者(对照组)的支气管肺泡灌洗液及血清中MMP-9及TIMP-1的含量,同时进行肺功能检查.结果:纤维化组患者的BALF及血清MMP-9的含量与对照组怠者相比无统计学意义,但纤维化组患者的BALF及血清TIMP-1的含量显著高于对照组(P<0.05),且纤雏化组患者的BALF及血清MMP-9/TIMP-1比值低于对照组(P<0.05).患者的动脉血氧分压、肺活量等肺功能指标与TIMP-1呈正相关,而与MMP-9/TIMP-1比值呈负相关(P<0.05).结论:肺结核患者肺纤维化的发生可能与TIMP-1水平升高及MMP-9/TIMP-1比值降低相关,降低TIMP-9的水平可能是防止肺结核惠者并发肺纤维化的一种新途径. 相似文献